XML 32 R21.htm IDEA: XBRL DOCUMENT
v3.25.1

STOCK-BASED COMPENSATION PLAN | 3 Months Ended
--- | ---
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract] |
STOCK-BASED COMPENSATION PLAN | STOCK-BASED COMPENSATION PLAN As of March 31, 2025, we had unvested stock options, restricted stock awards, performance-based restricted stock awards and restricted stock units granted under our stock-based compensation plans. On June 21, 2023, our stockholders approved the InTest Corporation 2023 Stock Incentive Plan (the “2023 Plan”) which replaced the Fourth Amended and Restated 2014 Stock Plan (the “2014 Plan”). No further awards can be granted under the 2014 Plan. The maximum number of shares of common stock available for grant and issuance under the 2023 Plan is (a) 350,000, plus (b) the number of shares of common stock available for issuance under the 2014 Plan on the date the 2023 Plan was approved by stockholders, plus (c) any shares of common stock that are subject to awards granted under the 2014 Plan that expire, are forfeited or canceled or terminate for any other reason on or after the date the 2023 Plan was approved by stockholders, without the issuance of shares. The number of shares available to be issued under the 2023 Plan as of the date of its approval was 1,117,942. Consistent with prior years’ performance-based awards, we reserve additional shares in the event that the performance achieves maximum levels. As a result of current year’s activity with regard to performance-based restricted stock awards (grants and forfeitures), we have 56,279 shares reserved in aggregate for performance in excess of target as of March 31, 2025. As of March 31, 2025, the remaining authorization for issue under the 2023 Plan was 396,431. The following table summarizes the compensation expense we recorded during the three months ended March 31, 2025 and 2024, related to unvested restricted stock, performance-based restricted stock awards, restricted stock units and stock options:
|  | Three Months Ended March 31,
(in thousands) |  | 2025 |  | 2024
Cost of revenues |  | $ | 38 |  |  | $ | 31 |
Selling expense |  | 13 |  |  | 11 |
Engineering and product development expense |  | (11) |  |  | 4 |
General and administrative expense |  | 383 |  |  | 303 |
|  | $ | 423 |  |  | $ | 349 |
As of March 31, 2025, total compensation expense to be recognized in future periods was $5.4 million. The weighted average period over which this expense is expected to be recognized was 2.9 years. There was no compensation expense capitalized in the three months ended March 31, 2025 or 2024. Stock Options The fair value for stock options granted during the three months ended March 31, 2025 and 2024 was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:
|  | Three Months Ended March 31,
|  | 2025 |  | 2024
Risk-free interest rate |  | 4.28 | % |  | 3.98 | %
Dividend yield |  | 0.00 | % |  | 0.00 | %
Expected common stock market price volatility factor |  | .59 |  | .57
Weighted average expected life of stock options (years) |  | 6.25 |  | 6.25
The following table summarizes the activity related to stock options for the three months ended March 31, 2025:
|  | Number of Shares |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Term (yrs) |  | Aggregate Intrinsic Value (in thousands)
Options outstanding, January 1, 2025 |  | 602,593 |  | $ | 10.92 |  |  |  |  |
Granted |  | 310,086 |  | 7.74 |  |  |  |  |
Exercised |  | (4,925) |  | 3.69 |  |  |  |  |
Canceled |  | (8,432) |  | 12.32 |  |  |  |  |
Options outstanding, March 31, 2025 |  | 899,322 |  | $ | 9.85 |  |  | 7.7 |  | $ | 102 |
Exercisable |  | 349,945 |  | $ | 10.54 |  |  | 6.5 |  | $ | 102 |
Expected to vest |  | 549,377 |  | $ | 9.41 |  |  | 8.5 |  | $ | — |
The table below summarizes certain additional information with respect to our options:
|  | Three Months Ended March 31,
(in thousands, except per option amounts) |  | 2025 |  | 2024
Weighted average grant date fair value per option |  | $ | 4.61 |  |  | $ | 6.55 |
Aggregate intrinsic value of options exercised |  | $ | 22 |  |  | $ | 40 |
Restricted Stock Awards The following table summarizes the activity related to unvested restricted stock awards for the three months ended March 31, 2025:
|  | Number of Shares |  | Weighted Average Grant Date Fair Value
Unvested shares outstanding, January 1, 2025 |  | 119,833 |  | $ | 11.92 |
Granted |  | 85,098 |  | 7.74 |
Vested |  | (31,745) |  | 12.12 |
Forfeited |  | (1,872) |  | 12.30 |
Unvested shares outstanding, March 31, 2025 |  | 171,314 |  | $ | 9.80 |
Additional information about our restricted stock awards is summarized as follows:
|  | Three Months Ended March 31,
(in thousands) |  | 2025 |  | 2024
Aggregate market value of RSA’s vested |  | $ | 250 |  |  | $ | 346 |
Performance-Based Restricted Stock Awards On January 16, 2024, the newly appointed president of our Process Technologies segment received performance-based restricted stock awards totaling 8,231 shares valued at $0.1 million as of the date of grant. These shares vest on the third anniversary of the grant date at a vesting percentage that could range from 0% to 150% of the number of shares of restricted stock awarded on January 16, 2024. The final vesting percentage will be based on the achievement of certain performance metrics including revenue and income from operations for specified time periods. As of March 31, 2025, we have estimated that these shares will vest at 100% of the original amount. On March 6, 2024, our CEO, CFO and the Division Presidents of our three operating segments received restricted stock awards totaling 33,539 shares valued at $0.4 million as of the date of grant. These shares vest on the third anniversary of the grant date at a vesting percentage that could range from 0% to 150% of the number of shares awarded on March 6, 2024. The final vesting percentage will be based on the achievement of certain performance metrics related to adjusted EBITDA for the year ended December 31, 2026, as determined by the Compensation Committee of our Board of Directors. At March 31, 2025, we have estimated that these shares will vest at 100% of the original amount based on our assessment of the probable achievement against the relevant performance metrics. On March 17, 2025, our CEO, CFO and the Division Presidents of our three operating segments received restricted stock awards totaling 49,098 shares valued at $0.4 million as of the date of grant. These shares vest on the third anniversary of the grant date at a vesting percentage that could range from 0% to 150% of the number of shares awarded on March 17, 2025. The final vesting percentage will be based on the achievement of certain performance metrics related to the percentage of revenue received by us generated by recurring revenue streams for the year ended December 31, 2027, as determined by the Compensation Committee of our Board of Directors. At March 31, 2025, we have estimated that these shares will vest at 100% of the original amount based on our assessment of the probable achievement against the relevant performance metrics. The following table summarizes the activity related to unvested performance-based restricted stock awards for the three months ended March 31, 2025:
|  | Number of Shares |  | Weighted Average Grant Date Fair Value
Unvested shares outstanding, January 1, 2025 |  | 88,949 |  | $ | 12.53 |
Granted |  | 49,098 |  | 7.74 |
Vested |  | — |  | — |
Forfeited |  | (25,493) |  | 10.17 |
Unvested shares outstanding, March 31, 2025 |  | 112,554 |  | $ | 10.97 |
Additional information about our performance-based restricted stock awards is summarized as follows:
|  | Three Months Ended March 31,
(in thousands) |  | 2025 |  | 2024
Aggregate market value of PSA’s vested |  | $ | — |  |  | $ | 117 |
Restricted Stock Units We began issuing restricted stock units to certain employees in 2025. The following table summarizes the activity related to unvested restricted stock awards for the three months ended March 31, 2025:
|  | Number of Shares |  | Weighted Average Grant Date Fair Value
Unvested shares outstanding, January 1, 2025 |  | — |  | $ | — |
Granted |  | 61,091 |  | 7.98 |
Vested |  | — |  | — |
Forfeited |  | — |  | — |
Unvested shares outstanding, March 31, 2025 |  | 61,091 |  | $ | 7.98 |
No RSUs vested during the three months ended March 31, 2025.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration